Candriam S.C.A. Acquires 3,517 Shares of Revvity, Inc. (NYSE:RVTY)

Candriam S.C.A. boosted its stake in Revvity, Inc. (NYSE:RVTY) by 39.2% during the fourth quarter, Holdings Channel.com reports. The firm owned 12,478 shares of the company’s stock after buying an additional 3,517 shares during the period. Candriam S.C.A.’s holdings in Revvity were worth $1,393,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in RVTY. Assetmark Inc. boosted its holdings in Revvity by 3,700.0% in the fourth quarter. Assetmark Inc. now owns 266 shares of the company’s stock valued at $30,000 after acquiring an additional 259 shares in the last quarter. Gladius Capital Management LP bought a new position in shares of Revvity during the third quarter valued at approximately $32,000. Continuum Advisory LLC increased its position in Revvity by 2,972.7% during the 3rd quarter. Continuum Advisory LLC now owns 338 shares of the company’s stock valued at $43,000 after buying an additional 327 shares in the last quarter. MassMutual Private Wealth & Trust FSB increased its holdings in Revvity by 55.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 385 shares of the company’s stock worth $43,000 after buying an additional 138 shares in the last quarter. Finally, Avior Wealth Management LLC raised its holdings in shares of Revvity by 7,980.0% during the third quarter. Avior Wealth Management LLC now owns 404 shares of the company’s stock valued at $52,000 after purchasing an additional 399 shares during the last quarter. 86.65% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Tajinder S. Vohra sold 5,492 shares of Revvity stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $116.81, for a total transaction of $641,520.52. Following the completion of the transaction, the insider now owns 19,652 shares of the company’s stock, valued at $2,295,550.12. The trade was a 21.84 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Joel S. Goldberg sold 15,170 shares of the stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $126.73, for a total value of $1,922,494.10. Following the sale, the insider now owns 33,400 shares in the company, valued at approximately $4,232,782. This trade represents a 31.23 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.60% of the company’s stock.

Revvity Stock Performance

NYSE RVTY opened at $117.95 on Monday. The company has a current ratio of 3.60, a quick ratio of 3.03 and a debt-to-equity ratio of 0.41. The stock has a market cap of $14.17 billion, a PE ratio of 53.37, a P/E/G ratio of 3.82 and a beta of 1.06. The stock has a fifty day simple moving average of $116.90 and a 200-day simple moving average of $118.21. Revvity, Inc. has a twelve month low of $97.32 and a twelve month high of $129.50.

Revvity (NYSE:RVTY) last issued its quarterly earnings results on Friday, January 31st. The company reported $1.42 EPS for the quarter, beating the consensus estimate of $1.37 by $0.05. Revvity had a net margin of 9.81% and a return on equity of 7.68%. During the same period in the previous year, the firm posted $1.25 earnings per share. Equities analysts anticipate that Revvity, Inc. will post 4.94 earnings per share for the current year.

Revvity Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, May 9th. Investors of record on Friday, April 18th will be given a $0.07 dividend. The ex-dividend date is Thursday, April 17th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.24%. Revvity’s dividend payout ratio (DPR) is presently 12.67%.

Analysts Set New Price Targets

A number of brokerages have commented on RVTY. Barclays upped their target price on shares of Revvity from $135.00 to $140.00 and gave the company an “overweight” rating in a report on Monday, February 3rd. Raymond James reissued an “outperform” rating and set a $145.00 price target (up from $140.00) on shares of Revvity in a research note on Monday, February 3rd. Bank of America raised shares of Revvity from a “neutral” rating to a “buy” rating and set a $138.00 price objective for the company in a research note on Friday, December 13th. KeyCorp increased their price target on Revvity from $132.00 to $145.00 and gave the company an “overweight” rating in a report on Monday, February 3rd. Finally, Sanford C. Bernstein downgraded shares of Revvity from an “outperform” rating to a “market perform” rating and set a $130.00 price objective for the company. in a research note on Friday, January 10th. Four investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Revvity has an average rating of “Moderate Buy” and a consensus target price of $136.25.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.